[Form 4] ABEONA THERAPEUTICS INC. Insider Trading Activity

Rhea-AI Filing Summary

Insider sales reported by Vishwas Seshadri, CEO and Director of Abeona Therapeutics (ABEO). The Form 4 shows two non-derivative sales: 19,274 shares sold on 09/29/2025 at a weighted average price of $5.3935 to cover tax obligations from restricted stock vesting, and 25,000 shares sold on 09/30/2025 at a weighted average price of $5.2372 under an existing Rule 10b5-1 trading plan. The reporting persons beneficial ownership decreased from 1,215,067 shares to 1,190,067 shares following these transactions. The filing is signed by Vishwas Seshadri on 10/01/2025.

Positive

• Timely and detailed disclosure of insider transactions, including weighted-average prices and explanations
• Use of a Rule 10b5-1 trading plan for one sale, indicating pre-established trading arrangements to avoid opportunistic timing

Negative

• Insider sold 44,274 shares (19,274 and 25,000) which reduced beneficial ownership from 1,215,067 to 1,190,067 shares

Insights

Corporate Governance Expert

TL;DR: Routine insider sales executed to meet tax obligations and under a pre-established 10b5-1 plan; disclosure is timely and standard practice.

The Form 4 discloses two stock sales by the CEO and Director, one to cover taxes on vested restricted stock and one executed automatically under a Rule 10b5-1 trading plan adopted on 09/18/2024. The disclosure includes weighted-average prices and the resulting reduction in beneficial ownership to 1,190,067 shares. From a governance perspective, use of a 10b5-1 plan and explicit explanation for tax-related sales are customary and consistent with maintaining an organized compliance posture. No derivative transactions or amendments are reported.

Securities Analyst

TL;DR: Insider sales occurred but were disclosed with required detail; no additional company financial data provided to assess broader impact.

The filing lists two disposals totaling 44,274 shares across two days with weighted-average sale prices in the $5.20$5.46 range. The report states the first sale covered tax obligations from restricted stock vesting and the second was under an established Rule 10b5-1 plan. The reduction in reported beneficial ownership is documented. This Form 4 provides clear transactional detail but contains no operating or financial results to evaluate material impact on the companys fundamentals.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Seshadri Vishwas

(Last) (First) (Middle)

6555 CARNEGIE AVE., 4TH FLOOR

(Street)

CLEVELAND OH 44103

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ABEONA THERAPEUTICS INC. [ ABEO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/29/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/29/2025		S(1)		19,274	D	$5.3935(2)	1,215,067	D
Common Stock	09/30/2025		S(3)		25,000	D	$5.2372(4)	1,190,067	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sale reported in this Form 4 was to cover tax obligations associated with the vesting of restricted stock awards.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.35 to $5.46 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

3. The reported sale of 25,000 shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 18, 2024.

4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.20 to $5.2725 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

	/s/ Vishwas Seshadri	10/01/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions were reported for ABEO on this Form 4?

The CEO and Director, Vishwas Seshadri, reported two sales: 19,274 shares on 09/29/2025 at a weighted average $5.3935 and 25,000 shares on 09/30/2025 at a weighted average $5.2372.

Why were the shares sold by Vishwas Seshadri?

The 19,274-share sale was to cover tax obligations from restricted stock vesting; the 25,000-share sale occurred automatically under a Rule 10b5-1 trading plan adopted 09/18/2024.

How did these transactions affect Seshadris ownership in ABEO?

Beneficial ownership decreased from 1,215,067 shares before the transactions to 1,190,067 shares after the reported sales.

Are there any derivative transactions reported in this filing?

No. Table II for derivative securities shows no transactions; only non-derivative common stock sales are reported.

When was the Form 4 signed and filed?

The filing is signed by Vishwas Seshadri on 10/01/2025 according to the document.